That is a possibility. When dealing with speculative biotech, short term movements have less to do with reality, and more to do with retail stupidity. People get caught up in hype without the ability to actually understand the science, or even to understand that they don't understand the science. My opinion is, and always will be, that I don't care what another stock does, or how much I could have made, I only care about how my stock performs, and I see no reason ONCS finishes the year below $1.
News 
Market Data 
Discover 
